Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Net Cash Flow (2016 - 2025)

BioCorRx's Net Cash Flow history spans 16 years, with the latest figure at $175816.0 for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 2224.66% year-over-year to $175816.0; the TTM value through Sep 2025 reached $287598.0, up 283.98%, while the annual FY2024 figure was $22811.0, 772.3% up from the prior year.
  • Net Cash Flow for Q3 2025 was $175816.0 at BioCorRx, up from $87730.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.3 million in Q1 2021 and bottomed at -$1.2 million in Q2 2021.
  • The 5-year median for Net Cash Flow is -$6383.0 (2023), against an average of -$16019.2.
  • The largest annual shift saw Net Cash Flow plummeted 1892.9% in 2023 before it skyrocketed 2224.66% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$659619.0 in 2021, then soared by 100.77% to $5086.0 in 2022, then tumbled by 1892.9% to -$91187.0 in 2023, then surged by 196.44% to $87943.0 in 2024, then skyrocketed by 99.92% to $175816.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Net Cash Flow are $175816.0 (Q3 2025), $87730.0 (Q2 2025), and -$63891.0 (Q1 2025).